- Home
- BCDA vs LPTX Comparison
BCDA vs LPTX Comparison
Compare BCDA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- LPTX
- Stock Information
- Founded
- BCDA N/A
- LPTX 2011
- Country
- BCDA United States
- LPTX United States
- Employees
- BCDA N/A
- LPTX N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCDA Health Care
- LPTX Health Care
- Exchange
- BCDA Nasdaq
- LPTX Nasdaq
- Market Cap
- BCDA 11.3M
- LPTX 11.1M
- IPO Year
- BCDA N/A
- LPTX N/A
- Fundamental
- Price
- BCDA $2.06
- LPTX $0.28
- Analyst Decision
- BCDA Strong Buy
- LPTX Hold
- Analyst Count
- BCDA 1
- LPTX 1
- Target Price
- BCDA $25.00
- LPTX N/A
- AVG Volume (30 Days)
- BCDA 62.9K
- LPTX 2.0M
- Earning Date
- BCDA 08-11-2025
- LPTX 08-14-2025
- Dividend Yield
- BCDA N/A
- LPTX N/A
- EPS Growth
- BCDA N/A
- LPTX N/A
- EPS
- BCDA N/A
- LPTX N/A
- Revenue
- BCDA N/A
- LPTX N/A
- Revenue This Year
- BCDA N/A
- LPTX N/A
- Revenue Next Year
- BCDA N/A
- LPTX N/A
- P/E Ratio
- BCDA N/A
- LPTX N/A
- Revenue Growth
- BCDA N/A
- LPTX N/A
- 52 Week Low
- BCDA $1.63
- LPTX $0.22
- 52 Week High
- BCDA $3.26
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- BCDA 56.99
- LPTX 44.35
- Support Level
- BCDA $1.90
- LPTX $0.27
- Resistance Level
- BCDA $1.99
- LPTX $0.31
- Average True Range (ATR)
- BCDA 0.08
- LPTX 0.02
- MACD
- BCDA 0.03
- LPTX 0.00
- Stochastic Oscillator
- BCDA 90.00
- LPTX 38.33
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.